Our mission at Berkeley BioLabs is to accelerate innovation in the sciences and sustainable technologies. As such, we’re delighted to support and/or to have co-founded the following innovative companies and projects:
Eric Babson (Professor of mathematics)
Eric is trying to build an oscillator in E. coli and the mathematicalmodel for it described in a paper of Hasty. The next step will be to try to figure out parameters that will impact features such as period, amplitude, stability, correlation with neighbors and whether it oscillates or switches. One target would be to see phase transitions in the behavior controlled by parameters such as medium, temperature, growth phase or crowding. Some parameters to change to try to achieve this would be adding signaling between cells, adjusting degradation rates and switching around promoters.More to come.
Leveraging simple and green chemistry that uses no reducing agents such as TCEP or DTT, Future Unity Labs is developing a new method for disulfide reduction which is a crucial step during bioconjugation. This technology has applications in biotechnology research and clinical drugs like Antibody Drug Conjugates (ADCs) and has already proven to be a fast and easy alternative to conventional methods.
Principal: David Martinez Moreno (designer/artist/bonzai expert)
David is designing bioengineered Bonsai portraitures of human subjects by introducing the portrayed person’s mitochondrial DNA into a bonsai.
The tree is chosen and shaped in its appearance to represent the subject’s character and personality. This Bonsai will host a piece of the subject’s DNA in its genome for as long as it lives. It is hard to tell with certainty how long a Bonsai lives. As far as we know, Bonsai rarely die unless through accidents or misfortunes unlike their wild counterparts.
The question of immortality through DNA demands further discussion enriched by the fact that the mitochondrial DNA holds information about the individual’s genealogy – where he/she comes from and arguably, who he/she is.
In collaboration with the scientific community at the Berkeley BioLabs, David has engaged in developing the technology necessary for this project.